BACKGROUND INFORMATION ON THE PROCEDURE 
1 
Submission of the dossier 
The applicant Janssen-Cilag International NV submitted on  4 May 2006  an application for Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Invega,  through  the  centralised 
procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised 
procedure was agreed upon by the EMEA/CHMP on 14 December 2005.  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain test(s) 
or study(ies). 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 24 July 2003. The Scientific Advice 
pertained to quality, non-clinical and clinical aspects of the dossier.  
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: Tomas Salmonson 
Co-Rapporteur: Karl Broich 
2 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 4 May 2006.  
The procedure started on 24 May 2006. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on 
8 August 2006 (Annex 4.1). The Co-Rapporteur's first Assessment Report was circulated to all 
CHMP members on 10 August 2006 (Annex 4.2). 
During the meeting from 18-21 September 2006, the CHMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on  21 September 2006 (Annex 4.3). 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
15 December 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on  26 January 2007 (Annex 4.4). 
During  the  CHMP  meeting  from  19-22  February  2007,  the  CHMP  agreed  on  a  list  of 
outstanding issues to be addressed in writing by the applicant (Annex 4.5). 
The  applicant  submitted  the  responses  to  the  CHMP  list  of  outstanding  issues  on 
27 March 2007. 
1/2 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
During the meeting from 23-26 April 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Invega  on  26  April  2007.  The  applicant  provided  the  letter  of 
undertaking  on 
fulfilled  post-authorisation  on 
19 April 2007 (Annex 4.6). 
follow-up  measures 
to  be 
the 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decision on 25 June 2007. 
2/2 
©EMEA 2007 
